Citations

Clear

4 citation(s) found for "Sharma, Neha".

IL-17A potentiates malignant T-cell viability via electron transport chain complex I in cutaneous T-cell lymphoma
Attrish, Diksha , Dhamija, Bhavuk , Mukherjee, Ditipriya , Sawant, Vinanti , Marathe, Soumitra , Saul, Dominik , Basu, Moumita , Banik, Ankit , Sharma, Neha , Shet, Tanuja, Jain, Hasmukh , Sharma, Priyanka , Purwar, Rahul , Saul, Dominik , Kosinsky, Robyn Laura

Mayo Clinic

No container title available | May 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.21.655309 Get It

Abstract Cutaneous T-cell lymphoma (CTCL) is a rare malignancy of skin-resident T cells characterized by an aberrant cytokine profile, notably elevated Interleukin-17A (IL-17A) levels. However, the functional importance of IL-17A dysregulation in the CTCL pathogenesis remains poorly understood. Our analysis revealed increased IL-17A receptor (IL-17RA) expression in CTCL patient samples, supporting the importance of IL-17A signaling in CTCL progression. Proteomic and metabolomic profiling of IL-17A-treated malignant T cells revealed mitochondrial electron transport chain (ETC) complex I as a key downstream target of IL-17A signaling. Furthermore, we confirmed the elevated expression of ETC complex I in CTCL patient samples compared to healthy control T cells, hence highlighting the clinical relevance of the IL-17A signaling-ETC complex 1 axis. Altogether, our data unveil the function of IL-17A signaling in the metabolic axis in CTCL progression, which could be useful for developing advanced therapeutic strategies. Significance statement: We uncover an IL-17A-induced electron transport chain (ETC) complex I pro-tumorigenic circuit and provide proof of concept evidence that ETC complex I can be targeted to combat the challenges posed by Cutaneous T-cell Lymphoma aggressiveness.
The Multistage Antimalarial Compound Calxinin Perturbates P. falciparum Ca2+ Homeostasis by Targeting a Unique Ion Channel
Gupta, Yash , Sharma, Neha , Singh, Snigdha , Romero, Jesús G., Rajendran, Vinoth , Mogire, Reagan M. , Kashif, Mohammad , Jeske, Walter , Poonam, Poonam , Ogutu, Bernhards , Kanzok, Stefan M. , Akala, Hoseah M. , Legac, Jennifer, Rosenthal, Philip J., Rademacher, David J., Durvasula, Ravi , Singh, Agam Prasad , Rathi, Brijesh , Kempaiah, Prakasha , Poonam , Akala, Hoseah M , Singh, Agam P , Rathi, Brijesh , Kempaiah, Prakasha , Gupta, Yash , Beach, Jordan R. , Rosenthal, Philip Jon

Mayo Clinic

Pharmaceutics | June 29, 2022 | Volume: 14 | Issue: 7 | Pages: 1371

10.3390/pharmaceutics14071371 | PMID 35890267 Get It

Malaria elimination urgently needs novel antimalarial therapies that transcend resistance, toxicity, and high costs. Our multicentric international collaborative team focuses on developing multistage antimalarials that exhibit novel mechanisms of action. Here, we describe the design, synthesis, and evaluation of a novel multistage antimalarial compound, ‘Calxinin’. A compound that consists of hydroxyethylamine (HEA) and trifluoromethyl-benzyl-piperazine. Calxinin exhibits potent inhibitory activity in the nanomolar range against the asexual blood stages of drug-sensitive (3D7), multidrug-resistant (Dd2), artemisinin-resistant (IPC4912), and fresh Kenyan field isolated Plasmodium falciparum strains. Calxinin treatment resulted in diminished maturation of parasite sexual precursor cells (gametocytes) accompanied by distorted parasite morphology. Further, in vitro liver-stage testing with a mouse model showed reduced parasite load at an IC50 of 79 nM. A single dose (10 mg/kg) of Calxinin resulted in a 30% reduction in parasitemia in mice infected with a chloroquine-resistant strain of the rodent parasite P. berghei. The ex vivo ookinete inhibitory concentration within mosquito gut IC50 was 150 nM. Cellular in vitro toxicity assays in the primary and immortalized human cell lines did not show cytotoxicity. A computational protein target identification pipeline identified a putative P. falciparum membrane protein (Pf3D7_1313500) involved in parasite calcium (Ca2+) homeostasis as a potential Calxinin target. This highly conserved protein is related to the family of transient receptor potential cation channels (TRP-ML). Target validation experiments showed that exposure of parasitized RBCs (pRBCs) to Calxinin induces a rapid release of intracellular Ca2+ from pRBCs; leaving de-calcinated parasites trapped in RBCs. Overall, we demonstrated that Calxinin is a promising antimalarial lead compound with a novel mechanism of action and with potential therapeutic, prophylactic, and transmission-blocking properties against parasites resistant to current antimalarials.
A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silico and in vitro investigations
Kumar, Sumit , Gupta, Yash , Zak, Samantha E. , Upadhyay, Charu, Sharma, Neha , Herbert, Andrew S. , Durvasula, Ravi , Poonam, Poonam , Kempaiah, Prakasha , Rathi, Brijesh , Potemkin, Vladimir , Poonam , Rathi, Brijesh , Kempaiah, Prakasha , Gupta, Yash , Herbert, Andrew S. , Dye, John M.

Mayo Clinic

RSC Medicinal Chemistry | August 18, 2021 | Volume: 12 | Issue: 10 | Pages: 1757-1764

10.1039/d1md00202c | PMID 34778776 Get It

A novel hydroxyethylamine compound was synthesised that displayed biological potency against SARS-CoV-2.
The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites
Gupta, Yash , Goicoechea, Steven , Pearce, Catherine M., Mathur, Raman, Romero, Jesús G., Kwofie, Samuel K., Weyenberg, Matthew C., Daravath, Bharathi, Sharma, Neha , Akala, Hoseah M. , Kanzok, Stefan M. , Durvasula, Ravi , Rathi, Brijesh , Kempaiah, Prakasha , Kempaiah, Prakasha , Rathi, Brijesh , Akala, Hoseah M , Kwofie, Samuel K , Gupta, Yash , Poonam, Poonam

Mayo Clinic

Medicinal Research Reviews | April 14, 2021 | Volume: 42 | Issue: 1 | Pages: 56-82

10.1002/med.21804 | PMID 33851452 Get It

AbstractCalcium channels (CCs), a group of ubiquitously expressed membrane proteins, are involved in many pathophysiological processes of protozoan parasites. Our understanding of CCs in cell signaling, organelle function, cellular homeostasis, and cell cycle control has led to improved insights into their structure and functions. In this article, we discuss CCs characteristics of five major protozoan parasites Plasmodium, Leishmania, Toxoplasma, Trypanosoma, and Cryptosporidium. We provide a comprehensive review of current antiparasitic drugs and the potential of using CCs as new therapeutic targets. Interestingly, previous studies have demonstrated that human CC modulators can kill or sensitize parasites to antiparasitic drugs. Still, none of the parasite CCs, pumps, or transporters has been validated as drug targets. Information for this review draws from extensive data mining of genome sequences, chemical library screenings, and drug design studies. Parasitic resistance to currently approved therapeutics is a serious and emerging threat to both disease control and management efforts. In this article, we suggest that the disruption of calcium homeostasis may be an effective approach to develop new anti‐parasite drug candidates and reduce parasite resistance.